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(28%), peripheral neuropathy (28%), and fatigue (24%). No 
treatment-related deaths were reported. Complete and par-
tial remissions were observed in 0/24 and 3/24 patients eli-
gible for efficacy analysis, respectively (ORR 13%). Progres-
sion-free survival was 2.9 months [95% confidence interval 
(95% CI) 1.9–4.2], and the median overall survival was 5.6 
months (95% CI 4.8–10.2).  Conclusion: The combination of 
paclitaxel and everolimus has not achieved the expected 
 efficacy in second-line treatment of urothelial cancer and 
should not be further explored.  © 2015 S. Karger AG, Basel 
 Introduction 
 Cisplatin-based combination chemotherapy has 
emerged as a standard up-front treatment of metastatic 
or advanced urothelial cancer within the last decades. 
The regimens most frequently applied are gemcitabine/
cisplatin, methotrexate/vinblastine/Adriamycin/cisplat-
in (MVAC), or dose-dense MVAC. The outcome of these 
 Key Words 
 Urothelial cancer · Chemotherapy · Platinum failure · 
Paclitaxel · Everolimus 
 Abstract 
 Objective: The efficacy of second-line treatment after failure 
of platinum-based chemotherapy in patients with advanced 
urothelial cancer is limited. Based on encouraging preclinical 
and clinical phase I data, we evaluated the safety and effi-
cacy of the combination of paclitaxel and everolimus in 
these patients.  Methods: In this trial, patients having failed 
to respond to prior platinum-based combination treatment 
of urothelial cancer were treated with paclitaxel (175 mg/m 2 
i.v., 3-weekly) and the mTOR-inhibitor everolimus (10 mg 
p.o., once daily). The patients were treated until tumor pro-
gression or until a maximum of 6 cycles was completed. A 
one-stage design was used to evaluate the objective re-
sponse rate (ORR) as the primary endpoint.  Results: A total 
of 27 patients (67% male; median age 63 years) were en-
rolled. The most frequent grade III/IV toxicities were anemia 
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combinations is comparable, resulting in an objective re-
sponse rate (ORR) of 50–60%, a median progression-free 
survival (PFS) of 8–10 months, and a median overall sur-
vival (OS) of 14–16 months  [1, 2] . In patients who are 
ineligible for cisplatin-based treatment regimens (e.g. 
due to impaired renal function or reduced performance 
status), a carboplatin-based combination treatment such 
as gemcitabine/carboplatin or methotrexate/carboplat-
in/vinblastine is the treatment of choice. However, this 
approach results in worse outcomes as compared to cis-
platin-based treatment strategies  [3] .
 After first-line treatment, a long-term response is ob-
served in <20% of patients, and relapse or progression 
occurs within the first 3 years  [1] . Subsequent second-line 
treatments are currently ill specified, and no accepted 
standard regimen has been defined. Recommended ther-
apeutic options apart from clinical studies include rein-
duction of cisplatin-based treatment in patients who had 
a relapse-free interval of 6 months or longer, or treatment 
with vinflunine. However, vinflunine has been approved 
only in Europe for second-line treatment of urothelial 
cancer after platinum failure  [4] . 
 An alternative second-line treatment approach might 
be the use of paclitaxel. Compared to vinflunine (ORR 
8.6%, PFS 3.0 months, OS 6.9 months), both paclitaxel 
monotherapy and paclitaxel-based combination treat-
ment have been observed to provide acceptable treatment 
efficacies (ORR 9–42%, PFS 2.2–5.5 months, OS 6.9–8.0 
months)  [4–7] . 
 In preclinical models, the efficacy of paclitaxel could 
be increased by the addition of everolimus  [8] . Everoli-
mus is an inhibitor of the PI3K/pAkt pathway targeting 
the serine/threonine kinase mTOR  [9] . This inhibitor is 
approved for the treatment of several metastatic tumors, 
e.g. renal cell carcinoma, breast cancer, and neuroendo-
crine pancreatic cancer. The tolerability and safety of 
everolimus in combination with paclitaxel have been test-
ed in two phase I trials in solid tumors  [10, 11] . 
 The aim of this phase II trial was to investigate the ef-
ficacy and safety of a combination therapy with paclitax-
el and everolimus in patients with platinum-refractory 
metastatic urothelial cancer.
 Subjects and Methods 
 Population 
 Eligible patients suffered from urothelial cancer of the upper or 
lower urinary tract and had failed to respond to prior platinum-
based combination chemotherapy including palliative, neoadju-
vant, and adjuvant treatment regimens. Other inclusion criteria 
were Eastern Cooperative Oncology Group performance status 
(ECOG PS) 0–2,  ≥ 1 measurable lesion according to the Response 
Evaluation Criteria in Solid Tumors version 1.0 (RECIST v1.0), 
and prior treatment with up to 4 chemotherapeutic drugs  [12] . The 
main exclusion criteria were the presence of a predominant histol-
ogy other than urothelial carcinoma and prior treatment with 
mTOR inhibitors or taxanes. Patients progressing within 3 months 
after neoadjuvant or adjuvant treatment were not eligible. The 
study protocol (CRAD001LDE17T, NCT00933374) was approved 
by the Ethics Committee at the Medical Faculty of the Heinrich 
Heine University, Düsseldorf, Germany. The protocol was fol-
lowed in accordance with the Declaration of Helsinki and Good 
Clinical Practice Guidelines.
 Assessments 
 Prior to the start of treatment, the patients were assessed for 
their medical and oncological history and ECOG PS  [13] . In addi-
tion, an evaluation of hematologic and biochemical parameters, 
urinalysis, electrocardiography, and a physical examination in-
cluding neurologic status were conducted. Tumor response and 
disease progression were measured at the baseline evaluation and 
at every other cycle every 6 weeks using the same imaging modal-
ity. Tumor response was assessed according to the RECIST v1.0 
 [12] . Toxicity and adverse events were classified according to the 
Common Terminology Criteria for Adverse Events (CTCAE) of 
the National Cancer Institute version 3.0 (http://ctep.cancer.gov/
forms/CTCAEv3.pdf). The patients’ reported quality of life was 
assessed using the European Organization for Research and Treat-
ment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) 
at baseline as well as at the beginning of each new treatment cycle 
 [14] .
 Treatment Plan 
 Eligible patients received paclitaxel (175 mg/m 2 i.v.) 3-weekly 
and everolimus (10 mg p.o.) daily as a continuous treatment. They 
were treated either until disease progression as defined by the 
 RECIST, until clinical disease progression, or until a maximum of 
6 cycles was reached. Treatment with everolimus was discontin-
ued in case of grade IV nonhematologic toxicity, grade IV throm-
bopenia, and grade IV febrile neutropenia. In case of dose-limit-
ing grade III toxicities (DLT), everolimus was reduced after recov-
ery (CTCAE grade  ≤ I) to 5 mg daily. If further DLT occurred, a 
reduction of the everolimus dose to 5 mg every other day was 
possible. Every further DLT led to a discontinuation of everoli-
mus treatment. The paclitaxel dose was reduced by 20% (to 140 
mg/m 2 ) for grade III/IV nonhematologic toxicity, grade III/IV fe-
brile neutropenia, grade IV neutropenia, or grade IV thrombope-
nia only if the everolimus dose had already been reduced once or 
been discontinued. In case of grade III/IV neuropathy, the pacli-
taxel dose was reduced independently from the everolimus dose 
adaptions. A delay of treatment of >21 days resulted in exclusion 
from the trial.
 Objectives 
 The primary objective was the ORR. Objective response was 
defined as either confirmed complete (CR) or confirmed partial 
remission (PR) as defined by the RECIST. ORR were analyzed in 
all patients having a relative dose intensity of  ≥ 50% during the first 
2 cycles.
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 The secondary objectives were OS, PFS, toxicity of combined 
treatment with paclitaxel and everolimus, and patients’ reported 
quality of life. OS, PFS, and patient-reported quality of life were 
analyzed in all patients included in this trial. Toxicities were ana-
lyzed in all patients who received  ≥ 1 dose of paclitaxel and/or 
everolimus.
 Statistics 
 This was a single-arm multicenter phase II trial. A one-stage 
design was used to evaluate the response rate. An ORR <20% was 
defined as ineffective (null hypothesis), an ORR  ≥ 40% was defined 
as effective (alternative hypothesis), assuming a higher efficacy of 
the combinatory treatment compared to paclitaxel monotherapy 
 [7, 15] . To reject the null hypothesis,  ≥ 7 objective responses (CR, 
PR) were required to be detected in 24 eligible patients (α = 10%, 
β = 80%). Assuming a dropout rate of 20%, 30 patients were 
planned to be included in this trial.
 The Kaplan-Meier product limit method was used to describe 
OS and PFS [medians, 95% confidence intervals (95% CI), and 
plots]. The OS and PFS of patients who did not have an event or 
receive any further anticancer therapy were censored at the date of 
the last adequate tumor assessment.
 Endpoints for the analyses of patient-reported outcomes were 
the global health status/quality-of-life scale scores as well as the 
functioning scales of the EORTC QLQ-C30. The analysis com-
prised a repeated measurement analysis of these scales for patients 
with  ≥ 1 postbaseline scale score. For statistical evaluation, a two-
way analysis of variance including Bonferroni’s posttest was used.
 The assessment of safety was based on the frequency of adverse 
events and on the number of laboratory values that fell outside of 
predetermined ranges. After inclusion of the first 6 patients, an 
interim analysis regarding DLT was conducted. Statistical analyses 
were conducted using R version 3.0.2 and GraphPad Prism version 
5.01.
 Results 
 Patient Characteristics 
 Between July 2009 and December 2011, 27 patients 
were accrued for this trial. The patients’ baseline charac-
teristics are detailed in  table 1 . All 27 patients were eligible 
for survival analysis (OS, PFS).
 Data on 24 patients were included in the efficacy anal-
ysis. Three patients were excluded as they received a <50% 
dose of treatment during the first 2 cycles. Two of them 
withdrew informed consent (1 patient before and 1 pa-
tient during the first cycle), and the third one needed to 
stop treatment before starting the second cycle due to 
herpes zoster which did not resolve within 21 days after 
discontinuation of the study treatment.
 The safety analysis included 25 patients who had re-
ceived  ≥ 1 dose of either paclitaxel or everolimus. Both 
patients who withdrew informed consent were not eligi-
ble for the safety analysis.
 Efficacy and Survival 
 The ORR in the 24 evaluable patients was 12.5%, with 
3 patients having a confirmed PR according to the  RECIST. 
No CR was observed. Since based on the one-stage design 
 ≥ 7 objective responses were required to be detected in the 
 Table 1. Patient and clinical baseline characteristics
Median age (range), years 63 (35 – 76)
Male:female ratio 18:9
Location of primary tumor
Lower urinary tract/bladder 16
Upper urinary tract 8
Both 3
Treatment
Surgical treatment of primary tumor 22
Ureterectomy, cystectomy 15
Nephrectomy, ureterectomy, 
nephroureterectomy 7
Biopsy/TURB only 5
Tumor grade (WHO 2004) at diagnosis
High grade 19
Low grade 2
Missing 6
ECOG PS
0 16
1 8
2 3
Bellmunt risk factors
0 9
1 7
2 5
3 6
Location of metastases
Liver 13
Lung 11
Bone 9
Lymph nodes 18
Other (including local recurrences) 7
Multiple sites 22
Prior treatment regimen
Gemcitabine/cisplatin 21
Gemcitabine/carboplatin 2
Other 4
>1 line of treatment 4
Intention of prior platinum-based treatment
Palliative 20
Perioperative 7
 Values are numbers unless specified otherwise. Bellmunt risk 
factors were evaluated as described previously [22]. TURB = 
Transurethral resection and biopsy.
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24 patients to assume an superior efficacy of the combina-
tion over paclitaxel monotherapy, the primary endpoint 
was not met. Stable disease (including 2 unconfirmed re-
sponses) was observed in 11 patients (45.8%), and pro-
gressive disease in 10 (41.7%). The duration of response 
and OS in the 3 PR patients were 1.8, 3.3, and 5.3 months 
and 7.4, 11.0, and 10.0 months, respectively. 
 Median OS and PFS were 5.6 months (95% CI 4.8–10.2) 
and 2.9 months (95% CI 1.9–4.2), respectively ( fig. 1 ). OS 
in patients with disease stabilization (PR/stable disease) 
was not different from that in PR patients. In all, 22/24 pa-
tients died during the treatment or within the 12-month 
follow-up period after termination of treatment. 
 In an additional exploratory analysis, no specific clini-
cal characteristics discriminating responders and nonre-
sponders could be identified ( table  2 ). PFS in patients 
with lower urinary tract urothelial cancer was shorter 
compared to that in patients with upper urinary tract uro-
thelial cancer, while OS and RECIST response were not 
different.
 Safety 
 Overall, 95 treatment cycles were administered. The 
median number of treatment cycles was 4 (range 1–6, in-
terquartile range 4). During the trial, 420 adverse events 
occurred in 25 patients. Grade III and grade IV toxicities 
were observed in 20 (80%) and 16 (64%) of the 25 pa-
tients, respectively. The most frequent adverse events ob-
served were hematologic disturbances (60%). Neutrope-
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 Fig. 1. OS and PFS in patients included in the efficacy analysis (n = 24). The Kaplan-Meier product limit method 
was used to describe OS and PFS. The Kaplan-Meier estimates are detailed as continuous lines, the 95% CIs as 
dotted lines.  a The median OS was 5.6 months (95% CI 4.8–10.2).  b The median PFS was 2.9 months (95% CI 
1.9–4.2). 
 Table 2. Comparison of responders and nonresponders
 Responders (patient ID) All other 
patients400 3 6004 7004
PFS, months 4.2 7.8 5.0 2.6a
OS, months 7.4 11.5 10.0 5.0a
Gender f f f 6 f/15 m
Age, years 54 71 73 63b
1st-line setting Peri Met Peri 8/21 Peri
Bellmunt risk factors, n 1 0 2 1b
ECOG PS 0 0 1 1b
Hb at baseline, g/dl 13.5 13.1 10.6 11.7b
Hepatic metastases yes no yes 9/21
Localization of
primary tumor
LT: 12/21
LT UT UT UT: 9/21
f = Female; m = male; Peri = perioperative 1st-line chemotherapy; 
Met = 1st-line chemotherapy for metastatic disease; LT = lower 
tract; UT = upper tract. a Median value obtained by Kaplan-Meier 
analysis. b Median value.
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nia and anemia were reported in 15 patients (60%) each, 
thrombopenia in 7 patients (28%) ( table 3 ). Further fre-
quent adverse events were pain (56%), peripheral neu-
ropathy (48%), and fatigue (48%). 
 Thirty-nine serious adverse event diagnoses were re-
ported in 12 patients; 8 of them may be related to the 
study medication (3 probably and 5 possibly; see  table 4 ). 
No treatment-related deaths were reported.
 Patient-Reported Quality of Life 
 During treatment, a temporary decline in physical 
(maximal change of absolute score: –11 points) and role 
functioning (maximal change of absolute score: –21 
points) was observed. However, neither differences be-
tween baseline and end-of-treatment status nor differ-
ences comparing statuses between treatment cycles were 
statistically significant. Global health status/quality of life 
as well as emotional, cognitive, and emotional function-
ing scales remained unchanged ( fig. 2 ).
 Discussion 
 The primary objective of this trial was to evaluate the 
efficacy of the combination of paclitaxel and everolimus 
in the treatment of patients suffering from advanced uro-
thelial cancer after failure of up-front platinum-based 
treatment, mainly using cisplatin. An objective response 
as defined by the RECIST in  ≥ 7 of the 24 eligible patients 
was required to assume a higher efficacy of the combina-
tory treatment compared to paclitaxel monotherapy  [7, 
15] . Accordingly, as only 3 confirmed PR were observed 
(ORR 12.5%), the trial result needs to be considered neg-
ative. Given reported response rates of 9–10% with a reg-
 Table 3. Overview of grade III and IV adverse events
Grade 
III
Grade 
IV
All 
grades
Hematological
Anemia 6 7 15
Neutropenia/leukopenia 7 4 15
Thrombopenia 1 2 7
Pain 4 3 14
Fatigue 5 6 12
Neurological
Peripheral sensory neuropathy 0 7 12
Dizziness 0 2 3
Skin
Alopecia 0 5 9
Acne 0 1 4
Dry skin 1 0 1
Gastrointestinal
Nausea/vomiting 2 2 8
Diarrhea 1 0 5
Constipation 0 1 4
Mucositis 1 0 3
Renal failure 4 1 4
Infections
Urinary tract infection 2 2 4
Pneumonia 1 0 2
Sepsis 2 0 2
Biliary tract infection 1 0 1
Kidney infection 0 1 1
Pneumonitis 0 1 1
Disturbed laboratory parameters
Elevated liver enzymes 1 4 4
Hypokalemia 1 0 2
Hypocalcemia 1 1 1
Hyponatremia 1 0 1
Hypothyroidism 0 1 1
Other
Dyspnea 1 1 3
Thrombosis 0 2 3
Hypertension 0 1 2
Ascites 1 0 1
Testicular operation 1 0 1
Ureteric stenosis 1 1 1
Numbers of patients in which the according adverse events 
were observed are provided.
 Table 4. Listing of serious adverse events potentially related to the 
study medication with CTCAE grade and outcome (not assessed)
Patient 
ID
Description of SAE CTCAE 
grade
Outcome
Probably related
4005 urinary tract infection 4 unknown
4007 neutrophil count
decreased 4 recovered/resolved
6003 general symptom NA recovered/resolved
Possibly related
2003 atrial fibrillation 2 recovered/resolved
4005 hemoglobin decreased 3 recovered/resolved
7002 sepsis 3 recovered/resolved
7002 hemoglobin decreased 4 recovered/resolved
7002 pneumonia 3 recovered/resolved
NA = Not applicable.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
5/
27
/2
01
6 
11
:2
3:
05
 A
M
 Paclitaxel and Everolimus as Second-Line 
Treatment in Urothelial Cancer 
Oncology 2015;89:70–78
DOI: 10.1159/000376551
75
imen of weekly paclitaxel (80 mg/m 2 , d1, d8, d15, q4w), 
everolimus did not seem to add any clinical benefit to 
paclitaxel treatment in terms of response rate  [7, 15] . 
 However, progressive disease seemed to occur less fre-
quently in our trial than reported from previous trials us-
ing paclitaxel monotherapy resulting in a disease control 
rate of nearly 60%  [7] . Similar effects were recently ob-
served in two trials using everolimus  [16, 17] and in one 
trial using temsirolimus  [18] , another mTOR inhibitor, 
as monotherapy for urothelial cancer. Despite only mar-
ginal ORR, relevant disease control rates (27–51%) were 
likewise observed. Nevertheless, in spite of encouraging 
preclinical data showing synergistic effects by combining 
everolimus with paclitaxel, the results of our trial were 
below our expectations  [8] .
 Typical everolimus-related toxicities (stomatitis, rash, 
fatigue, noninfectious pneumonitis) occurred in the ex-
pected range and were comparable to those observed in 
both trials investigating everolimus monotherapy for 
urothelial cancer  [16, 17] as well as in a phase III trial 
evaluating everolimus as salvage treatment for metastatic 
renal cell carcinoma  [19] . The frequency of typical pacli-
taxel-related adverse events, e.g. peripheral neuropathy, 
also did not seem to be increased  [7] . In contrast, hema-
tologic toxicities, especially neutropenia and anemia, 
were more frequent than has been reported for both 
 paclitaxel and everolimus monotherapy  [7, 16, 17, 19] . 
These findings are also in accordance with data from oth-
er trials investigating combination treatment with pacli-
taxel and everolimus  [10, 20] . This suggests that cumula-
tive bone marrow toxicity must be expected when these 
two compounds are combined, and this should be con-
sidered in further trials of combination treatment. 
 Concerning the quality-of-life analysis, our results are 
in line with the findings by other groups. For example, 
neither treatment with vinflunine nor treatment with 
 paclitaxel after failure of up-front platinum-based treat-
ment of urothelial cancer has been reported to impair pa-
tients’ health-related quality of life (although significant 
toxicities were observed with both treatments and should 
have an impaired quality of life)  [4, 7] . Merging quality-
of-life data from the AUO trials AB 35/09 (paclitaxel + 
everolimus) and 20/99 (gemcitabine + paclitaxel), we 
have recently confirmed these results as well  [21] . In cis-
platin-based first-line treatment, von der Maase et al.  [22] 
observed a stable health-related quality of life in patients 
undergoing treatment with either MVAC or gemcitabine/
cisplatin, with no differences between the two patient 
groups. For the second large phase III trial of up-front 
treatment for urothelial cancer comparing MVAC to 
high-dose-intensity MVAC, no data on health-related 
quality of life have been reported  [23] . 
 In our trial, the PFS of patients undergoing treatment 
with paclitaxel and everolimus was comparable to that 
with other taxane-based treatment regimens as well as 
monotherapy with vinflunine (2.2–5.5 months). Howev-
er, the OS of 5.6 months was lower than that reported in 
these trials (6.9–8.0 months)  [4, 7, 15, 24] . As an initial 
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 Fig. 2. Change in quality-of-life dimension 
scores with time. The various lines indicate 
the mean score values for the particular di-
mensions of the EORTC QLQ-C30. EOT = 
End of treatment. 
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response to treatment with disease stabilization was ob-
served in more than half of the patients and no treatment-
related deaths were reported, this finding might be attrib-
utable to the poor prognostic factors observed in our co-
hort rather than to the efficacy of the treatment regimen. 
About three quarters of the patients in this trial suffered 
from visceral metastases (74%), and >80% had multior-
gan involvement. In comparison, visceral metastases and 
multiorgan involvement were less frequent in the largest 
trial of paclitaxel monotherapy (58 and 67%, respectively) 
and in a phase III trial comparing short-term and long-
term combinatorial treatment with paclitaxel and gem-
citabine (38 and 46%, respectively)  [7, 25, 26] . In addi-
tion, 41% of the patients presented with 2 or 3 poor prog-
nostic factors (Hb  ≤ 10 g/dl, liver metastases, ECOG PS 
 ≥ 1) compared to 33 and 23% in the vinflunine phase III 
and the gemcitabine/paclitaxel trial, respectively  [25, 26] . 
 Despite initial enthusiasm regarding inhibition of the 
PI3K/Akt/mTOR signaling pathway as a suitable targeted 
approach in urothelial cancer, it must be concluded from 
4 recent phase II trials that the clinical efficacy of mTOR 
inhibitors in this disease has been modest at best  [16–18] . 
This is surprising, given the recent finding of mutations 
(both activating and inactivating) of several key enzymes 
of PI3K/Akt/mTOR signaling by the Cancer Genome At-
las project in a number of cases  [27] . Interestingly, an ac-
tivity of mTOR inhibitors has been reported in at least 
some urothelial cancer patients, given 3 PR and 1 CR after 
everolimus monotherapy as well as a relevant disease 
control rate in two phase II trials  [16, 17] . This raises the 
question of how those patients who have the highest like-
lihood of experiencing benefits from the use of an mTOR 
inhibitor might be identified. Concomitant molecular in-
vestigations to resolve this issue have yielded inconsistent 
results in urothelial cancer. While in the trial by Seront 
et al.  [16] , an association between loss of PTEN and re-
sponse to everolimus was suggested, Milowsky et al.  [17] 
were not able to confirm this observation. An analysis of 
the tumor genome of 1 urothelial bladder cancer patient 
with CR after treatment with everolimus monotherapy 
revealed mutations in the  TSC1 gene, an upstream inhib-
itor of the mTOR signaling pathway  [28] . Interestingly, 
an increased rate of  TSC1 mutations in patients with ra-
diographic treatment response was also observed in a 
small validation cohort of patients in the same trial. Pro-
spective validation is warranted to clarify whether this 
finding may help to identify patients who might benefit 
from mTOR inhibitors in the future. 
 An alternative explanation for the apparently low fre-
quency of responders to mTOR inhibition might be the 
observation of an Akt-dependent, but mTOR-indepen-
dent, regulation of 4EBP1  [29] . Accordingly, the use of 
inhibitors of upstream regulators of mTOR activity, i.e. 
targeting Akt itself, may be a more promising approach 
in patients in whom tumor progression is suspected to 
depend on PI3K/Akt/mTOR signaling.
 Evaluating the results of our analysis, several flaws and 
limitations need to be considered. Certainly, the main 
points are the limited patient number and the long time 
frame for the recruitment of patients. One potential rea-
son for this might have been the introduction of vinflu-
nine on the market in Germany in 2009. Further potential 
reasons might have been the general reluctance of treat-
ing physicians to refer palliative patients who have failed 
up-front cisplatin-based treatment and generally present 
in a poor condition for further toxic treatment. However, 
this trial was primarily designed to detect a first efficacy 
signal as well as statistical measures to capture this signal, 
e.g. an α failure of 10% and a rather low target ORR of 
20%.
 In conclusion, the combination of paclitaxel and 
everolimus has failed to demonstrate the expected effi-
cacy in second-line treatment of urothelial cancer. Apart 
from an increased number of hematologic adverse events, 
the toxicities were comparable to those observed with 
other second-line treatment options. Clinical factors for 
the prediction of treatment response remain elusive. Un-
til predictive biomarkers will be available to guide the use 
of inhibitors targeting the PI3K/Akt/mTOR signaling 
pathway, mTOR inhibitors should not be further tested 
as a treatment option in an unselected population of pa-
tients with advanced urothelial cancer.
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